Research Use Only. The information on this page summarizes published peptide research for laboratory and educational reference. The compounds discussed are intended exclusively for in vitro and non-clinical research. Nothing on this page constitutes medical advice or describes human use, diagnosis, treatment, or therapeutic application.
Overview
What is BPC-157? It is a 15-amino-acid synthetic pentadecapeptide isolated as a fragment of a larger gastric juice protein, and the most extensively studied tissue-repair peptide in the contemporary peptide research literature. The published research base spans rodent injury models, cellular signaling studies, and methodology work going back to the early 1990s. BPC-157 has become the reference compound for tissue-repair peptide research and the most common entry point for researchers new to the recovery peptide category.
This article covers what BPC-157 is at the structural and biochemical level, the proposed mechanisms of action documented in published research, the model systems most commonly used for BPC-157 work, and the methodology considerations that govern rigorous in vitro and pre-clinical research with the compound. It sits within the GENEVIUM Research Hub coverage of recovery and tissue-repair peptide research, in the Healing & Sleep pillar. For the broader research-use-only framework that governs all GENEVIUM peptides, see What Research Use Only Means.
What Is BPC-157 at the Molecular Level
BPC-157 stands for Body Protection Compound 157. The name reflects the compound origin: BPC-157 was identified as a 15-amino-acid fragment of a larger gastric juice protein during research at the University of Zagreb in the 1990s. The parent protein was named Body Protection Compound based on observed protective effects in gastric mucosa research, and the 157 designation refers to the position within the parent protein sequence where the active fragment was identified.
Sequence and Synthesis
The amino acid sequence of BPC-157 is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. The peptide is described as a pentadecapeptide because it contains fifteen amino acid residues. The sequence is unusually proline-rich, with five proline residues in the first eight positions, which contributes to a distinctive secondary structure and to the compound chemical stability.
Synthetic BPC-157 used in research is produced by solid-phase peptide synthesis using standard fluorenylmethoxycarbonyl (Fmoc) chemistry. The peptide is then purified by reverse-phase HPLC to research-grade purity standards (typically minimum 99% by reverse-phase HPLC) and characterized by mass spectrometry to confirm sequence identity. The synthesis route does not require unusual amino acid building blocks or specialized chemistry, which is part of why BPC-157 has become widely available as a research compound.
Stability and Solubility
BPC-157 is unusually stable for a peptide of its size. The proline-rich sequence contributes to resistance against protease cleavage, and the absence of cysteine residues means there is no disulfide bond chemistry to manage. Published stability data document that BPC-157 retains activity in gastric juice and across a range of pH conditions that would degrade most peptide compounds, which is one of the distinguishing features of the molecule.
Solubility in aqueous research buffers is good. Standard reconstitution uses bacteriostatic water or sterile saline, and reconstituted BPC-157 retains stability at refrigerator temperatures over the time course of typical research experiments. Long-term storage of lyophilized BPC-157 is at minus 20 degrees Celsius or lower in dry conditions.
Proposed Mechanisms of Action
BPC-157 mechanism research has progressed substantially since the original gastric mucosa work. The published literature now documents effects across multiple cellular signaling pathways and tissue contexts, although the specific molecular target or targets remain incompletely characterized. The current understanding treats BPC-157 as a multi-mechanism compound rather than a selective ligand for a single receptor.
Nitric Oxide Pathway Modulation
A substantial body of published research documents BPC-157 effects on the nitric oxide (NO) signaling system. The compound has been shown to interact with NO synthase activity and downstream NO-mediated processes including vasodilation, endothelial cell function, and certain anti-inflammatory pathways. The NO-pathway connection is one of the most consistently reproduced mechanism findings in BPC-157 research and is implicated in the effects observed on vascular and gastrointestinal endpoints.
Growth Factor and Angiogenic Signaling
BPC-157 has been studied for effects on growth factor expression and angiogenic signaling, including vascular endothelial growth factor (VEGF) pathway activity. Pre-clinical research using endothelial cell migration assays and rodent wound healing models has documented enhanced angiogenesis in BPC-157-treated samples relative to controls. The mechanistic linkage between BPC-157 and angiogenic pathway engagement is consistent with the tissue-repair phenotype observed across multiple injury models.
Receptor Pharmacology and the Open Question
Unlike compounds in the incretin agonist family where receptor pharmacology is well-characterized, BPC-157 does not have a definitively established primary receptor target. Published research has investigated several candidate receptors and binding partners, but no single receptor accounts for the full range of effects observed. The compound is currently best described as engaging multiple signaling pathways rather than a single receptor system, which has implications for experimental design: comparative experiments using receptor-knockout models or selective receptor antagonists can be inconclusive because the relevant target may not be the receptor being manipulated.
Areas of Active BPC-157 Research
The published BPC-157 research literature spans several distinct areas, each with its own characteristic model systems and endpoints. Researchers new to BPC-157 work benefit from understanding which areas have the strongest published evidence base before designing their own experimental protocols.
Tendon and Ligament Research
Tendon-to-bone healing and ligament repair models are among the most extensively studied applications of BPC-157 in pre-clinical research. Rat Achilles tendon transection models, medial collateral ligament rupture models, and tendon-to-bone reattachment paradigms have all been used to characterize BPC-157 effects on connective tissue repair. The published findings consistently document accelerated healing endpoints in BPC-157-treated animals relative to vehicle controls, although the specific cellular mechanism continues to be characterized.
Gastrointestinal Research
The original BPC-157 research focused on gastric mucosa protection, and gastrointestinal injury models remain a major area of contemporary work. Research has examined intestinal anastomosis healing, esophagogastric anastomosis models, colitis models, and gastric ulcer models. The combination of mucosal protection and tissue-repair effects in the GI context is the basis for the original “Body Protection Compound” naming and remains the most mechanistically detailed area of BPC-157 research.
Muscle Injury and Repair
Crush injury models and muscle laceration models in rodents have been used to characterize BPC-157 effects on skeletal muscle repair. Published research documents accelerated functional recovery and improved histological repair markers in BPC-157-treated muscle tissue. The mechanistic basis is hypothesized to involve a combination of angiogenic signaling, anti-inflammatory pathway engagement, and effects on satellite cell biology, although the exact contributions of each pathway continue to be characterized.
Vascular and Cardiovascular Endpoints
A growing body of research examines BPC-157 effects on vascular endothelial function, blood vessel formation, and cardiovascular endpoints in rodent models. The connection to nitric oxide signaling discussed above is particularly relevant in this research area, where NO-mediated vasodilation and endothelial protection mechanisms are direct mechanistic readouts. Researchers studying angiogenic mechanisms across both tissue-repair compounds in parallel can find the dedicated overview at What Is TB-500.
Research Methodology and Quality Standards
BPC-157 research is sensitive to compound purity and identity confirmation. The proline-rich sequence and the relatively short peptide length mean that synthesis errors, sequence variants, or contamination with truncation products can substantially alter biological activity. Published research consistently uses minimum 99% purity by reverse-phase HPLC, with mass spectrometric identity confirmation matching the theoretical molecular weight, as the standard threshold for tissue-repair peptide work.
Reconstitution methodology should be standardized within and across studies. Bacteriostatic water and sterile saline are the most common reconstitution media. The final concentration and the time elapsed between reconstitution and use should be reported in published research, since stability over hours to days at refrigerator temperature is good but not unlimited. Repeated freeze-thaw cycles should be avoided.
Standard model systems for BPC-157 research include rodent injury models for in vivo characterization (rat Achilles tendon, rat MCL, mouse colitis models, and others depending on research question), endothelial cell preparations for vascular and angiogenic endpoints, and gastric mucosa preparations for the historically foundational gastrointestinal research. Cell-based assays should specify the cell line or primary preparation used and the relevant pathway readouts, since BPC-157 effects span multiple signaling systems and the choice of readout determines what can be observed.
For methodology specific to BPC-157 used alongside TB-500 in tissue-repair research, see BPC-157 and TB-500 Research. For coverage of multi-peptide research formulations including BPC-157, TB-500, and GHK-Cu, see Glow Peptide Research. For the broader recovery peptide category context, see Recovery Peptide Research.
GENEVIUM publishes a batch-specific Certificate of Analysis for every research peptide and makes them retrievable by batch number on the COA Lookup Page.
Frequently Asked Questions
What does BPC-157 stand for?
BPC-157 stands for Body Protection Compound 157. The name was given during the original research at the University of Zagreb in the 1990s, when the compound was identified as a 15-amino-acid fragment of a larger gastric juice protein observed to have protective effects on gastric mucosa. The 157 designation refers to the position within the parent protein sequence where the active fragment was located.
What is the BPC-157 amino acid sequence?
The sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, fifteen amino acids in total. The sequence is described as proline-rich because of the five proline residues in the first eight positions, which contributes to the unusual chemical stability of the molecule.
Why is BPC-157 called a pentadecapeptide?
Pentadecapeptide is the technical term for a peptide containing fifteen amino acid residues. The Greek prefix penta- means five and deca- means ten, combining to specify a fifteen-residue peptide. BPC-157 is therefore properly described as a pentadecapeptide in the published research literature.
What pre-clinical model systems are most commonly used in BPC-157 research?
Rodent injury models dominate the in vivo BPC-157 research literature, including rat Achilles tendon transection, rat medial collateral ligament rupture, mouse colitis models, gastric ulcer models, and muscle crush injury paradigms. In vitro work commonly uses endothelial cell preparations for vascular and angiogenic endpoints, and gastric mucosa preparations for the historically foundational gastrointestinal research line.
Are GENEVIUM research peptides intended for human use?
No. All GENEVIUM peptides are research-use-only compounds intended exclusively for laboratory research, in vitro work, and non-clinical investigation. They are not approved for, and are not to be used for, human consumption, therapeutic application, or any clinical purpose.
What Is BPC-157? Research Overview of the Pentadecapeptide
What Is BPC-157? Research Overview of the Pentadecapeptide
Overview
What is BPC-157? It is a 15-amino-acid synthetic pentadecapeptide isolated as a fragment of a larger gastric juice protein, and the most extensively studied tissue-repair peptide in the contemporary peptide research literature. The published research base spans rodent injury models, cellular signaling studies, and methodology work going back to the early 1990s. BPC-157 has become the reference compound for tissue-repair peptide research and the most common entry point for researchers new to the recovery peptide category.
This article covers what BPC-157 is at the structural and biochemical level, the proposed mechanisms of action documented in published research, the model systems most commonly used for BPC-157 work, and the methodology considerations that govern rigorous in vitro and pre-clinical research with the compound. It sits within the GENEVIUM Research Hub coverage of recovery and tissue-repair peptide research, in the Healing & Sleep pillar. For the broader research-use-only framework that governs all GENEVIUM peptides, see What Research Use Only Means.
What Is BPC-157 at the Molecular Level
BPC-157 stands for Body Protection Compound 157. The name reflects the compound origin: BPC-157 was identified as a 15-amino-acid fragment of a larger gastric juice protein during research at the University of Zagreb in the 1990s. The parent protein was named Body Protection Compound based on observed protective effects in gastric mucosa research, and the 157 designation refers to the position within the parent protein sequence where the active fragment was identified.
Sequence and Synthesis
The amino acid sequence of BPC-157 is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. The peptide is described as a pentadecapeptide because it contains fifteen amino acid residues. The sequence is unusually proline-rich, with five proline residues in the first eight positions, which contributes to a distinctive secondary structure and to the compound chemical stability.
Synthetic BPC-157 used in research is produced by solid-phase peptide synthesis using standard fluorenylmethoxycarbonyl (Fmoc) chemistry. The peptide is then purified by reverse-phase HPLC to research-grade purity standards (typically minimum 99% by reverse-phase HPLC) and characterized by mass spectrometry to confirm sequence identity. The synthesis route does not require unusual amino acid building blocks or specialized chemistry, which is part of why BPC-157 has become widely available as a research compound.
Stability and Solubility
BPC-157 is unusually stable for a peptide of its size. The proline-rich sequence contributes to resistance against protease cleavage, and the absence of cysteine residues means there is no disulfide bond chemistry to manage. Published stability data document that BPC-157 retains activity in gastric juice and across a range of pH conditions that would degrade most peptide compounds, which is one of the distinguishing features of the molecule.
Solubility in aqueous research buffers is good. Standard reconstitution uses bacteriostatic water or sterile saline, and reconstituted BPC-157 retains stability at refrigerator temperatures over the time course of typical research experiments. Long-term storage of lyophilized BPC-157 is at minus 20 degrees Celsius or lower in dry conditions.
Proposed Mechanisms of Action
BPC-157 mechanism research has progressed substantially since the original gastric mucosa work. The published literature now documents effects across multiple cellular signaling pathways and tissue contexts, although the specific molecular target or targets remain incompletely characterized. The current understanding treats BPC-157 as a multi-mechanism compound rather than a selective ligand for a single receptor.
Nitric Oxide Pathway Modulation
A substantial body of published research documents BPC-157 effects on the nitric oxide (NO) signaling system. The compound has been shown to interact with NO synthase activity and downstream NO-mediated processes including vasodilation, endothelial cell function, and certain anti-inflammatory pathways. The NO-pathway connection is one of the most consistently reproduced mechanism findings in BPC-157 research and is implicated in the effects observed on vascular and gastrointestinal endpoints.
Growth Factor and Angiogenic Signaling
BPC-157 has been studied for effects on growth factor expression and angiogenic signaling, including vascular endothelial growth factor (VEGF) pathway activity. Pre-clinical research using endothelial cell migration assays and rodent wound healing models has documented enhanced angiogenesis in BPC-157-treated samples relative to controls. The mechanistic linkage between BPC-157 and angiogenic pathway engagement is consistent with the tissue-repair phenotype observed across multiple injury models.
Receptor Pharmacology and the Open Question
Unlike compounds in the incretin agonist family where receptor pharmacology is well-characterized, BPC-157 does not have a definitively established primary receptor target. Published research has investigated several candidate receptors and binding partners, but no single receptor accounts for the full range of effects observed. The compound is currently best described as engaging multiple signaling pathways rather than a single receptor system, which has implications for experimental design: comparative experiments using receptor-knockout models or selective receptor antagonists can be inconclusive because the relevant target may not be the receptor being manipulated.
Areas of Active BPC-157 Research
The published BPC-157 research literature spans several distinct areas, each with its own characteristic model systems and endpoints. Researchers new to BPC-157 work benefit from understanding which areas have the strongest published evidence base before designing their own experimental protocols.
Tendon and Ligament Research
Tendon-to-bone healing and ligament repair models are among the most extensively studied applications of BPC-157 in pre-clinical research. Rat Achilles tendon transection models, medial collateral ligament rupture models, and tendon-to-bone reattachment paradigms have all been used to characterize BPC-157 effects on connective tissue repair. The published findings consistently document accelerated healing endpoints in BPC-157-treated animals relative to vehicle controls, although the specific cellular mechanism continues to be characterized.
Gastrointestinal Research
The original BPC-157 research focused on gastric mucosa protection, and gastrointestinal injury models remain a major area of contemporary work. Research has examined intestinal anastomosis healing, esophagogastric anastomosis models, colitis models, and gastric ulcer models. The combination of mucosal protection and tissue-repair effects in the GI context is the basis for the original “Body Protection Compound” naming and remains the most mechanistically detailed area of BPC-157 research.
Muscle Injury and Repair
Crush injury models and muscle laceration models in rodents have been used to characterize BPC-157 effects on skeletal muscle repair. Published research documents accelerated functional recovery and improved histological repair markers in BPC-157-treated muscle tissue. The mechanistic basis is hypothesized to involve a combination of angiogenic signaling, anti-inflammatory pathway engagement, and effects on satellite cell biology, although the exact contributions of each pathway continue to be characterized.
Vascular and Cardiovascular Endpoints
A growing body of research examines BPC-157 effects on vascular endothelial function, blood vessel formation, and cardiovascular endpoints in rodent models. The connection to nitric oxide signaling discussed above is particularly relevant in this research area, where NO-mediated vasodilation and endothelial protection mechanisms are direct mechanistic readouts. Researchers studying angiogenic mechanisms across both tissue-repair compounds in parallel can find the dedicated overview at What Is TB-500.
Research Methodology and Quality Standards
BPC-157 research is sensitive to compound purity and identity confirmation. The proline-rich sequence and the relatively short peptide length mean that synthesis errors, sequence variants, or contamination with truncation products can substantially alter biological activity. Published research consistently uses minimum 99% purity by reverse-phase HPLC, with mass spectrometric identity confirmation matching the theoretical molecular weight, as the standard threshold for tissue-repair peptide work.
Reconstitution methodology should be standardized within and across studies. Bacteriostatic water and sterile saline are the most common reconstitution media. The final concentration and the time elapsed between reconstitution and use should be reported in published research, since stability over hours to days at refrigerator temperature is good but not unlimited. Repeated freeze-thaw cycles should be avoided.
Standard model systems for BPC-157 research include rodent injury models for in vivo characterization (rat Achilles tendon, rat MCL, mouse colitis models, and others depending on research question), endothelial cell preparations for vascular and angiogenic endpoints, and gastric mucosa preparations for the historically foundational gastrointestinal research. Cell-based assays should specify the cell line or primary preparation used and the relevant pathway readouts, since BPC-157 effects span multiple signaling systems and the choice of readout determines what can be observed.
For methodology specific to BPC-157 used alongside TB-500 in tissue-repair research, see BPC-157 and TB-500 Research. For coverage of multi-peptide research formulations including BPC-157, TB-500, and GHK-Cu, see Glow Peptide Research. For the broader recovery peptide category context, see Recovery Peptide Research.
GENEVIUM publishes a batch-specific Certificate of Analysis for every research peptide and makes them retrievable by batch number on the COA Lookup Page.
Frequently Asked Questions
What does BPC-157 stand for?
BPC-157 stands for Body Protection Compound 157. The name was given during the original research at the University of Zagreb in the 1990s, when the compound was identified as a 15-amino-acid fragment of a larger gastric juice protein observed to have protective effects on gastric mucosa. The 157 designation refers to the position within the parent protein sequence where the active fragment was located.
What is the BPC-157 amino acid sequence?
The sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, fifteen amino acids in total. The sequence is described as proline-rich because of the five proline residues in the first eight positions, which contributes to the unusual chemical stability of the molecule.
Why is BPC-157 called a pentadecapeptide?
Pentadecapeptide is the technical term for a peptide containing fifteen amino acid residues. The Greek prefix penta- means five and deca- means ten, combining to specify a fifteen-residue peptide. BPC-157 is therefore properly described as a pentadecapeptide in the published research literature.
What pre-clinical model systems are most commonly used in BPC-157 research?
Rodent injury models dominate the in vivo BPC-157 research literature, including rat Achilles tendon transection, rat medial collateral ligament rupture, mouse colitis models, gastric ulcer models, and muscle crush injury paradigms. In vitro work commonly uses endothelial cell preparations for vascular and angiogenic endpoints, and gastric mucosa preparations for the historically foundational gastrointestinal research line.
Are GENEVIUM research peptides intended for human use?
No. All GENEVIUM peptides are research-use-only compounds intended exclusively for laboratory research, in vitro work, and non-clinical investigation. They are not approved for, and are not to be used for, human consumption, therapeutic application, or any clinical purpose.